Compare Oscar Health Inc (OSCR) vs Unilever plc (UL) Price & Performance

Oscar Health (OSCR) trades at $33.01, up 2.36% today and approaching its 52-week high of $33.10. The stock shows strong technical momentum with bullish moving averages and has surged 109% year-to-date. Fundamentally, revenue grew from $11.7B in 2025 to $15.3B in 2026, with net income turning positive at $551M. Recent earnings beats and membership growth to 2.96 million support the bullish case, though valuation metrics like P/E of 25.39 and P/B of 4.97 suggest premium pricing.

Outlook remains positive with strong revenue growth and profitability improvements, but risks include high valuation multiples and dependence on sustained membership growth. Analyst consensus is mixed with 27% buy ratings and a $30.67 price target below current levels, indicating caution despite technical strength. Key catalysts include continued operational efficiency gains and AI integration, while medical cost management remains critical.

Unilever (UL) trades at $63.54, down 1.03% on the day, with a bullish technical signal from moving averages but neutral oscillators. Recent earnings misses contrast with strong profitability, including a net income margin of 18.32% and ROE of 54.57% for 2025. The company reported its strongest quarterly volume growth in over a decade in Q2 2026, raising its full-year outlook, while strategic shifts include focusing on beauty and personal care and a planned $65 billion merger with McCormick.

The outlook is mixed: robust fundamentals and strategic refocusing support long-term growth, particularly in emerging markets, but consistent earnings misses and a high P/E ratio of 21.46 pose valuation concerns. Risks include integration challenges from the McCormick deal and competitive pressures. Analyst consensus is divided, with 24% buy ratings, highlighting cautious optimism amid execution uncertainties.